Sandbox Reserved 1847

From Proteopedia

(Difference between revisions)
Jump to: navigation, search

Revision as of 19:07, 27 March 2025

This Sandbox is Reserved from March 18 through September 1, 2025 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson and Mark Macbeth at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1828 through Sandbox Reserved 1846.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Contents

Structure

Introduction

What are Minibinders?

Minibinders are small proteins that bind to the spike protein that is involved in the viral infection pathway for SARS-CoV-2. These mini proteins target the interaction between SARS-CoV-2 spike protein and ACE2 receptor as an effective therapeutic strategy [1]. The demand for SARS-CoV-2 therapeutics is high, and the promise these minibinders have shown is substantial. These minibinders were able to reduce the viral burden of SARS-CoV-2 in mice [2]. These proteins were de novo (from scratch) designs to mimic the ACE2 helix, but have a lower dissociation constant (greater affinity for spike protein)[1].

COVID-19 Viral Infection Interruption

Subheading 2

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 Mar 30. pii: 10.1038/s41586-020-2180-5. doi:, 10.1038/s41586-020-2180-5. PMID:32225176 doi:http://dx.doi.org/10.1038/s41586-020-2180-5
  2. Case JB, Chen RE, Cao L, Ying B, Winkler ES, Goreshnik I, Shrihari S, Kafai NM, Bailey AL, Xie X, Shi PY, Ravichandran R, Carter L, Stewart L, Baker D, Diamond MS. Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice. bioRxiv [Preprint]. 2021 Mar 1:2021.03.01.433110. PMID:33688650 doi:10.1101/2021.03.01.433110
  3. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  4. Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
  5. Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020 Oct 23;370(6515):426-431. PMID:32907861 doi:10.1126/science.abd9909
Personal tools